Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 
Julie E. Chang, MD close
FeBCWunywYQ
Julie E. Chang, MD
 

New Patients

Need help selecting a primary care doctor? Contact the Welcome Center for personal assistance.

For Referring Physicians

How to refer a patient

Julie E. Chang, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Chang joined the University of Wisconsin as an Assistant Professor in 2007. After graduating from Indiana University School of Medicine, she completed her internal medicine residency and hematology and oncology fellowships at the University of Wisconsin. Dr. Chang treats a wide range of cancers, but has special interest in lymphoma and complications of cancer involving the central nervous system. She is actively participating in further developing the Lymphoma Research Program at the University of Wisconsin Carbone Cancer Center.

Specialties

Hematology

Medical Oncology

Brain Tumor Care

Hematology (Leukemia, Lymphoma and Multiple Myeloma)

Hematology (non cancer)

Leukemia, Lymphoma, Multiple Myeloma

Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
Richland Hospital
(608) 647-6321 | | Map
Richland Hospital
(608) 647-6321 | | Map

Hospital Affiliation(s)

University Hospital
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Indiana University School of Medicine, Indianapolis, IN

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Chang is part of the UW Lymphoma Research Program, through which multiple clinical trials are focusing on developing improved treatment options for patients with lymphoma. Dr. Chang's research interests include lymphoma, experimental therapeutics and complications of cancer involving the central nervous system.


PubMed Articles
Chang JE Carmichael LL Kim K Peterson C Yang DT Traynor AM Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk . 2018 Jan;18(1):e61-e67
[PubMed ID: 29191715]
Abaza YM Kadia TM Jabbour EJ Konopleva MY Borthakur G Ferrajoli A Estrov Z Wierda WG Alfonso A Chong TH Chuah C Koh LP Goh BC Chang JE Durkes DE Foudray MC Kantarjian HM Dong XQ Garcia-Manero G Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer . 2017 Dec 15;123(24):4851-4859
[PubMed ID: 28841236]
Chang JE Maintenance lenalidomide could be most relevant after first-line therapy. Lancet Haematol . 2017 Nov;4(11):e502-e503
[PubMed ID: 28958468]
Advani RH Lebovic D Chen A Brunvand M Goy A Chang JE Hochberg E Yalamanchili S Kahn R Lu D Agarwal P Dere RC Hsieh HJ Jones S Chu YW Cheson BD Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clin Cancer Res . 2017 Mar 1;23(5):1167-1176
[PubMed ID: 27601593]
Chang JE Havighurst T Kim K Eickhoff J Traynor AM Kirby-Slimp R Volk LM Werndli J Go RS Weiss M Blank J Kahl BS Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. Br J Haematol . 2016 Apr;173(2):283-91
[PubMed ID: 26913697]
Zent CS Victoria Wang X Ketterling RP Hanson CA Libby EN Barrientos JC Call TG Chang JE Liu JJ Calvo AR Lazarus HM Rowe JM Luger SM Litzow MR Tallman MS A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol . 2016 Mar;91(3):308-12
[PubMed ID: 26662208]
Chang JE Li H Smith MR Gascoyne RD Paietta EM Yang DT Advani RH Horning SJ Kahl BS Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood . 2014 Mar 13;123(11):1665-73
[PubMed ID: 24458437]
Chang JE Kahl BS PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep . 2014 Mar;9(1):33-43
[PubMed ID: 24390602]
Lake W Chang JE Kennedy T Morgan A Salamat S BaÅŸkaya MK A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics. Neurosurgery . 2013 Jun;72(6):960-70; discussion 970
[PubMed ID: 23685504]
Chang JE Kahl BS Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother . 2012 Jul;13(10):1495-505
[PubMed ID: 22663160]
Chang JE Kahl BS Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma . 2012 Jul;53(7):1249-50
[PubMed ID: 22220986]
Chang JE Kahl BS Current status of targeted therapies for mantle cell lymphoma. Drugs . 2011 Dec 3;71(17):2307-26
[PubMed ID: 22085387]
Leal T Chang JE Mehta M Robins HI Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Curr Cancer Ther Rev . 2011 Nov;7(4):319-327
[PubMed ID: 23251128]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol . 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
Lepeak LM Yang DT Chang JE Extranodal NK/T-cell lymphoma presenting with primary cardiac involvement. Hematol Rep . 2011 Aug 31;3(2):e9
[PubMed ID: 22184541]
Cassaday RD Malik JT Chang JE Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk . 2011 Jun;11(3):289-92
[PubMed ID: 21658658]
Visco C Hoeller S Malik JT Xu-Monette ZY Wiggins ML Liu J Sanger WG Liu Z Chang J Ranheim EA Gradowski JF Serrano S Wang HY Liu Q Dave S Olsen B Gascoyne RD Campo E Swerdlow SH Chan WC Tzankov A Young KH Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component. Am J Surg Pathol . 2011 Feb;35(2):177-89
[PubMed ID: 21263238]
Chang JE Seo S Kim KM Werndli JE Bottner WA Rodrigues GA Sanchez FA Saphner TJ Longo WL Kahl BS Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk . 2010 Oct;10(5):379-84
[PubMed ID: 21030351]
Chang JE Medlin SC Kahl BS Longo WL Williams EC Lionberger J Kim K Kim J Esterberg E Juckett MB Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma . 2008 Dec;49(12):2298-307
[PubMed ID: 19052977]
Chang JE Juckett MB Callander NS Kahl BS Gangnon RE Mitchell TL Longo WL Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma . 2008 Jun;8(3):153-8
[PubMed ID: 18650178]